{"id":380251,"date":"2020-11-12T16:08:18","date_gmt":"2020-11-12T21:08:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380251"},"modified":"2020-11-12T16:08:18","modified_gmt":"2020-11-12T21:08:18","slug":"trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/","title":{"rendered":"Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors"},"content":{"rendered":"<h2>\nIndustry Veteran Brings Deep Executive and Commercial Experience to Trillium Board<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., Nov.  12, 2020  (GLOBE NEWSWIRE) &#8212; <strong>Trillium<\/strong><strong> Therapeutics Inc.<\/strong><strong> (\u201cTrillium\u201d or the \u201cCompany\u201d)<\/strong><strong> (NASDAQ\/TSX: TRIL), <\/strong>a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Paolo Pucci to its Board of Directors, effective immediately. Mr. Pucci has significant expertise in oncology drug development and decades of leadership experience across large and small organizations over his 30 year career.<\/p>\n<p align=\"justify\">\u201cWe are delighted to welcome Mr. Pucci to the board of directors\u201d said Robert L. Kirkman, M.D., Chair of Trillium Therapeutics. \u201cHis broad executive and commercial expertise, specifically in the field of oncology, will be invaluable as Trillium prepares for later stage clinical development.\u201d<\/p>\n<p align=\"justify\">Most recently, Mr. Pucci served as Chief Executive Officer of the targeted therapeutics oncology company, ArQule, until it was acquired by Merck for $2.7 billion in January 2020. Prior to ArQule, Mr. Pucci served in a number of leadership positions at Bayer AG from 2001 to 2008, including President of the Oncology &amp; Global Specialty Medicines Business Units and was a member of the Bayer Pharmaceuticals Global Management Committee. Mr. Pucci also held multiple roles at Eli Lily and Company from 1991 to 2001.<\/p>\n<p align=\"justify\">Mr. Pucci received his M.S. in economics and accounting from Universit\u00e0 degli Studi di Napoli Federico II and an MBA in marketing and finance from the University of Chicago. He currently serves as a board member of West Pharmaceuticals Services Inc., Merus N.V. and Replimune Inc., and had previous board roles at NewLink Genetics Inc., Dyax Inc. and Algeta ASA.<\/p>\n<p align=\"justify\">\u201cI look forward to contributing my knowledge in oncology drug development and commercialization over the coming years,\u201d said Mr. Pucci. \u201cThere has never been a more exciting time to be developing novel oncology agents, and Trillium is well positioned in the field.\u201d<\/p>\n<p align=\"justify\">\n        <strong>A<\/strong><br \/>\n        <strong>bout Trillium Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company\u2019s two clinical programs, TTI-621 and TTI-622,\u00a0target CD47, a \u201cdon\u2019t eat me\u201d signal that cancer cells frequently use to evade the immune system.<\/p>\n<p align=\"justify\">For more information visit: <a href=\"http:\/\/www.trilliumtherapeutics.com\/\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.trilliumtherapeutics.com<\/a>\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations<\/strong><br \/>\n        <strong>:<\/strong><br \/>\n        <br \/>James Parsons<br \/>Chief Financial Officer<br \/>Trillium Therapeutics Inc. <br \/>416-595-0627 x232<br \/><a href=\"mailto:james@trilliumtherapeutics.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">james@trilliumtherapeutics.com<\/a><br \/><a href=\"http:\/\/www.trilliumtherapeutics.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.trilliumtherapeutics.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Relations:<\/strong><br \/>\n        <br \/>Mike Beyer<br \/>Sam Brown Inc.<br \/>312-961-2502<br \/><a href=\"mailto:mikebeyer@sambrown.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mikebeyer@sambrown.com<\/a><\/p>\n<p align=\"justify\">\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMwNSMzODI1MTMxIzIwMjc0ODc=\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Trillium Therapeutics Inc. (\u201cTrillium\u201d or the \u201cCompany\u201d) (NASDAQ\/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Paolo Pucci to its Board of Directors, effective immediately. Mr. Pucci has significant expertise in oncology drug development and decades of leadership experience across large and small organizations over his 30 year career. \u201cWe are delighted to welcome Mr. Pucci to the board of directors\u201d said Robert L. Kirkman, M.D., Chair of Trillium Therapeutics. \u201cHis broad executive and commercial expertise, specifically in the field of oncology, will be invaluable as Trillium &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380251","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Trillium Therapeutics Inc. (\u201cTrillium\u201d or the \u201cCompany\u201d) (NASDAQ\/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Paolo Pucci to its Board of Directors, effective immediately. Mr. Pucci has significant expertise in oncology drug development and decades of leadership experience across large and small organizations over his 30 year career. \u201cWe are delighted to welcome Mr. Pucci to the board of directors\u201d said Robert L. Kirkman, M.D., Chair of Trillium Therapeutics. \u201cHis broad executive and commercial expertise, specifically in the field of oncology, will be invaluable as Trillium &hellip; Continue reading &quot;Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-12T21:08:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMwNSMzODI1MTMxIzIwMjc0ODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors\",\"datePublished\":\"2020-11-12T21:08:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\\\/\"},\"wordCount\":396,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTMwNSMzODI1MTMxIzIwMjc0ODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\\\/\",\"name\":\"Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTMwNSMzODI1MTMxIzIwMjc0ODc=\",\"datePublished\":\"2020-11-12T21:08:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTMwNSMzODI1MTMxIzIwMjc0ODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTMwNSMzODI1MTMxIzIwMjc0ODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors - Market Newsdesk","og_description":"Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) &#8212; Trillium Therapeutics Inc. (\u201cTrillium\u201d or the \u201cCompany\u201d) (NASDAQ\/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Paolo Pucci to its Board of Directors, effective immediately. Mr. Pucci has significant expertise in oncology drug development and decades of leadership experience across large and small organizations over his 30 year career. \u201cWe are delighted to welcome Mr. Pucci to the board of directors\u201d said Robert L. Kirkman, M.D., Chair of Trillium Therapeutics. \u201cHis broad executive and commercial expertise, specifically in the field of oncology, will be invaluable as Trillium &hellip; Continue reading \"Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-12T21:08:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMwNSMzODI1MTMxIzIwMjc0ODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors","datePublished":"2020-11-12T21:08:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/"},"wordCount":396,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMwNSMzODI1MTMxIzIwMjc0ODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/","name":"Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMwNSMzODI1MTMxIzIwMjc0ODc=","datePublished":"2020-11-12T21:08:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMwNSMzODI1MTMxIzIwMjc0ODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTMwNSMzODI1MTMxIzIwMjc0ODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trillium-therapeutics-appoints-paolo-pucci-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380251"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380251\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}